Korro Bio Chief Executive Officer Ram Aiyar, Ph.D., MBA, to Present at 2021 Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. EDT.

The event will be livestreamed on the Jefferies website, and streaming access will be available for 30 days following the presentation.

About Korro Bio, Inc.

Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. The synthetic oligonucleotide platform, OPERA^TM, is a modular drug discovery engine that combines proprietary data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.